Service Predicts Tablet Tooling Sticking Problems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Service Predicts Tablet Tooling Sticking Problems



I Holland has announced the TSAR Predict service, which offers a solution to stop tablet tooling sticking problems, the company reports. The service examines the API or main component of a formulation and prepares a solution by reviewing factors including Van Der Waals, capillary action and morphology. The service was developed after the completion of a two-year Tableting Science Anti-Stick Research (TSAR) project in collaboration with the University of Nottingham's School of Pharmacy and professionals from the Laboratory of Biophysics and Surface Analysis in the UK. The aim of the project was to investigate and solve the universal tablet-manufacturing problem of sticking. The information has now resulted in a service that forecasts the correct anti-stick PharmaCote coating solution for any formulation.

Source: I Holland

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here